Keyphrases
Chronic Kidney Disease
100%
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
100%
Low-density Lipoprotein Cholesterol (LDL-C)
100%
Valvular Heart Disease
100%
Renal Failure
100%
MitraClip
50%
Valvular Disease
33%
Percutaneous Approach
16%
Heart Failure Mortality
16%
Prevention Strategies
16%
Inclusion Criteria
16%
Disease Experience
16%
Safety Profile
16%
Accelerated Courses
16%
End-stage Renal Disease
16%
Kidney Disease
16%
Percutaneous Management
16%
Aortic Valve
16%
Secondary Mitral Regurgitation
16%
Percutaneous Intervention
16%
Severe Mitral Regurgitation
16%
Heart Failure Hospitalization
16%
Mitral Valve Repair
16%
COAPT Trial
16%
Heart Valve
16%
Valve Disease
16%
Dialysis Initiation
16%
Kidney Injury
16%
Enhanced Awareness
16%
Medical Therapy
16%
Kidney Function
16%
High Prevalence
16%
Valvular Calcification
16%
Worse Outcome
16%
Severe Aortic Stenosis
16%
Patient Management
16%
Patient Selection
16%
Dialysis Patients
16%
Cholesterol Levels
16%
Transthoracic Echocardiography
16%
Mitral Valve
16%
Postoperative Follow-up
16%
Transcatheter Aortic Valve Replacement
16%
Kidney Disease Progression
16%
Surgical Intervention
16%
Mitral Annular Calcification
16%
Valve Intervention
16%
Surgical Aortic Valve Replacement
16%
Surgical Management
16%
Symptomatic Heart Failure
16%
Medicine and Dentistry
Proprotein Convertase 9
100%
Low Density Lipoprotein Cholesterol
100%
Renal Failure
100%
Chronic Kidney Disease
100%
Valvular Heart Disease
100%
Population
28%
Mitral Insufficiency
28%
Congestive Heart Failure
28%
Diseases
14%
Awareness
14%
Transthoracic Echocardiography
14%
End Stage Renal Disease
14%
Patient Care
14%
Aortic Valve
14%
Kidney Injury
14%
Kidney Function
14%
Patient Population
14%
Prevalence
14%
Nephropathy
14%
Valve Replacement
14%
Aortic Stenosis
14%
Mitral Valve
14%
Combination Therapy
14%
Percutaneous Intervention
14%
Aortic Valve Replacement
14%
Mitral Valve Surgery
14%
Dyslipidemia
8%
C-Peptide
8%
Linear Regression Analysis
8%
Immunoassay
8%
Statin
8%
Receptor
8%
